Last Updated: September 24, 2026

Drug Sales Trends for OXYBUTYNIN

✉ Email this page to a colleague

« Back to Dashboard

Payment Methods and Pharmacy Types for OXYBUTYNIN (2014)

Revenues by Pharmacy Type

Chart
Table

Pharmacy Type	Revenues
MAIL-ORDER	$101,837,728
INSIDE ANOTHER STORE	$49,467,097
[disabled in preview]	$215,255,986
This preview shows a limited data set Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Chart
Table

Pharmacy Type	Units
MAIL-ORDER	951,962
INSIDE ANOTHER STORE	1,570,397
[disabled in preview]	3,894,379
This preview shows a limited data set Subscribe for full access, or try a Trial

Revenues by Payment Method

Chart
Table

Payment Method	Revenues
MEDICAID	$38,078,969
MEDICARE	$208,839,521
[disabled in preview]	$106,749,933
This preview shows a limited data set Subscribe for full access, or try a Trial

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Drug Sales Revenue Trends for OXYBUTYNIN

Drug Units Sold Trends for OXYBUTYNIN

Annual Sales Revenues and Units Sold for OXYBUTYNIN

These sales figures are drawn from a US national survey of drug expenditures

Subscribe to access the full database, or Start Trial
Drug Name	Revenues (USD)	Units	Year
OXYBUTYNIN	⤷ Start Trial	⤷ Start Trial	2022
OXYBUTYNIN	⤷ Start Trial	⤷ Start Trial	2021
OXYBUTYNIN	⤷ Start Trial	⤷ Start Trial	2020
>Drug Name	>Revenues (USD)	>Units	>Year

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.